Blockbuster BeiGene Cancer Drug Adds Another FDA Approval
The FDA approved BeiGene’s Brukinsa as a treatment for advanced cases of follicular lymphoma. It’s the fifth FDA nod for the drug, which has become BeiGene’s top-selling product.
BeiGene’s Phase III Waldenström’s study misses mark, but with a possible silver lining
The Phase III study showed that BeiGene's Brukinsa outperformed AbbVie and J&J's Imbruvica on safety. An analyst wrote that FDA approval on that basis is unlikely, but off-label prescribing is possible. Brukinsa won approval for another blood cancer last month.
Changes in Nurse Staffing Answer Clinician Demands
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.